Is AstraZeneca blackmailing Europe?
The Trump administration’s drug policy continues to impact the Old Continent, and Big Pharma is riding the wave. After Pfizer, AstraZeneca also threatens Europe with delays in launching new therapies if spending on innovative medicines does not increase.
AstraZeneca will surpass Roche in hormone therapies for breast cancer.
The failure to meet the endpoint in the phase 3 study on giredestrant causes Roche shares to drop by up to 7.5% and reignites competition with AstraZeneca in the market for new hormonal therapies for breast cancer. Facts, figures, and comments.
